ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Systemic Sclerosis and Related Disorders – Clinical Poster II

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 1730
A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases
9:00AM-11:00AM
Abstract Number: 1732
Alterations of Body Composition in Patients with Systemic Scleroderma Are Associated with Disease Activity, Physical Activity and Serum Levels of Inflammatory Cytokines
9:00AM-11:00AM
Abstract Number: 1734
Association of Short-Term Longitudinal Changes in Clinical and Physiologic Variables with Overall Survival in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
9:00AM-11:00AM
Abstract Number: 1738
Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension
9:00AM-11:00AM
Abstract Number: 1735
Diagnostic Accuracy of MR Angiography in a Cohort with Systemic Sclerosis Compared to Other Rheumatic Diseases with Acral Hypoperfusion
9:00AM-11:00AM
Abstract Number: 1741
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1742
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1724
Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series
9:00AM-11:00AM
Abstract Number: 1740
Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
9:00AM-11:00AM
Abstract Number: 1716
Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo
9:00AM-11:00AM
Abstract Number: 1717
Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study
9:00AM-11:00AM
Abstract Number: 1725
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis- a Pilot Study
9:00AM-11:00AM
Abstract Number: 1719
High-Throughput Quantitative Histology in Systemic Sclerosis Skin Disease Using Computer Vision
9:00AM-11:00AM
Abstract Number: 1720
Higher Neutrophil Count Predicts More Severe Skin/Lung Disease and Increased Mortality in Early Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1736
Incidence and Risk Factors for Gangrene in Patients with Systemic Sclerosis from the Eustar Cohort
9:00AM-11:00AM
Abstract Number: 1729
Increased Risk of Valvular Heart Disease in Patients with Systemic Sclerosis: Results from a Population-Based Cohort (1980-2016)
9:00AM-11:00AM
Abstract Number: 1723
Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
9:00AM-11:00AM
Abstract Number: 1737
Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide
9:00AM-11:00AM
Abstract Number: 1722
Patient-Level Factors Associated with Hospital Readmission Among Patients with Systemic Sclerosis Associated Pulmonary Hypertension
9:00AM-11:00AM
Abstract Number: 1728
Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation
9:00AM-11:00AM
Abstract Number: 1744
Prognostic Value of Right Heart Involvement in Systemic Sclerosis:Not Only Pulmonary Arterial Hypertension
9:00AM-11:00AM
Abstract Number: 1727
Prospective Confirmation of Potential Link between Proton Pump Inhibitor Exposure and Calcinosis in Systemic Sclerosis
9:00AM-11:00AM
Abstract Number: 1721
Racial Differences in SSc Disease Presentation: A Cross-Sectional European Scleroderma Trials and Research Group Study
9:00AM-11:00AM
Abstract Number: 1715
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
9:00AM-11:00AM
Abstract Number: 1743
Serum Markers Potentially Associated with PAH in Systemic Sclerosis; A Targeted Screening Approach
9:00AM-11:00AM
Abstract Number: 1726
Sexual Dysfunction in Systemic Sclerosis Female Patients
9:00AM-11:00AM
Abstract Number: 1733
Should We Perform Exercise Echocardiogram As a Screening Test for Pulmonary Arterial Hypertension (PAH) for All Systemic Sclerosis (SSc) Patients?
9:00AM-11:00AM
Abstract Number: 1718
Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change
9:00AM-11:00AM
Abstract Number: 1731
Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma
9:00AM-11:00AM
Abstract Number: 1739
What Do Patient Reported Outcomes for Routine Monitoring of Gastrointestinal Tract Symptoms in a Systemic Sclerosis Center Tell Us about Clinical Features of Potential Small Intestinal Bacterial Overgrowth?

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology